Lonza Group AG Logo

Lonza Group AG

A global CDMO for the pharmaceutical, biotech, and nutrition industries.

LONN | SW

Overview

Corporate Details

ISIN(s):
CH0013841017 (+2 more)
LEI:
549300EFW4H2TCZ71055
Country:
Switzerland
Address:
MÜNCHENSTEINERSTR. 38, 4052 BASEL

Description

Lonza Group AG is a global contract development and manufacturing organization (CDMO) that partners with the pharmaceutical, biotech, and nutrition industries. The company provides integrated services that span the entire product lifecycle, from early-phase research and process development to custom, large-scale commercial manufacturing. Its expertise covers a wide range of therapeutic modalities, including mammalian and microbial biopharmaceuticals, small molecules, cell and gene therapies, highly potent active pharmaceutical ingredients (APIs), peptides, and bioconjugates. By combining advanced scientific and technological insights with world-class manufacturing and regulatory expertise, Lonza supports its customers in developing and commercializing innovative medicines and health products for patients worldwide.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-23 06:30
Lonza Delivers a Strong Q3 2025 and Confirms Full-Year 2025 Outlook for its CDM…
English 18.3 KB
2025-10-23 02:00
Lonza Delivers a Strong Q3 2025 and Confirms Full-Year 2025 Outlook for its CDM…
English 15.5 KB
2025-10-03 09:00
Lonza Nominates Claudia Sussmuth-Dyckerhoff as Board Member
English 17.8 KB
2025-10-03 02:00
Lonza Nominates Claudia Süssmuth-Dyckerhoff as Board Member
English 14.2 KB
2025-09-12 09:00
Lonza Appoints Jason Berndt as Head of Group Operations, and Maria Soler Nunez …
English 22.8 KB
2025-09-12 02:00
Lonza Appoints Jason Berndt as Head of Group Operations, and Maria Soler Nunez …
English 18.8 KB
2025-07-23 06:30
Lonza Delivers Strong H1 2025 Performance and Upgrades 2025 Full-Year CDMO Sale…
English 42.2 KB
2025-07-23 02:00
Lonza Delivers Strong H1 2025 Performance and Upgrades 2025 Full-Year CDMO Sale…
English 37.0 KB
2025-07-23 02:00
Lonza erzielt starkes Ergebnis im ersten Halbjahr 2025 und erhöht Umsatz- und M…
German 36.9 KB
2025-05-27 07:00
Lonza Publishes 2024 Comparative Financials Under One Lonza Organizational Stru…
English 12.7 KB
2025-05-27 02:00
Lonza Publishes 2024 Comparative Financials Under One Lonza Organizational Stru…
English 9.7 KB
2025-05-15 09:00
Lonza Appoints Andreas Bohrer as Chief Legal & Corporate Affairs Officer
English 14.6 KB
2025-05-15 02:00
Lonza Appoints Andreas Bohrer as Chief Legal & Corporate Affairs Officer
English 11.0 KB
2025-05-10 16:30
Lonza Announces Results of the 2025 Annual General Meeting All Motions Propose…
English 16.3 KB
2025-05-09 06:30
Lonza Q1 2025 Qualitative Update: Strong Performance Across All Businesses in L…
English 15.2 KB

Automate Your Workflow. Get a real-time feed of all Lonza Group AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Lonza Group AG

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Lonza Group AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-03-14 N/A Executive member Buy None 147,442.00 CHF
2025-03-13 N/A Executive member Buy None 107,906.00 CHF
2025-03-12 N/A Executive member Buy None 146,239.00 CHF
2025-03-11 N/A Executive member Buy None 382,476.00 CHF
2025-03-10 N/A Executive member Buy None 771,722.40 CHF
2025-03-07 N/A Executive member Buy None 338,476.00 CHF
2025-03-06 N/A Executive member Buy None 313,416.00 CHF
2025-02-18 N/A Executive member Buy None 164,554.00 CHF
2025-02-14 N/A Executive member Buy None 130,606.00 CHF
2025-02-13 N/A Executive member Buy None 29,500.00 CHF

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.